190 related articles for article (PubMed ID: 9412303)
1. Reversibility of hepatic fibrosis in autoimmune hepatitis.
Dufour JF; DeLellis R; Kaplan MM
Ann Intern Med; 1997 Dec; 127(11):981-5. PubMed ID: 9412303
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and pathological characteristics and outcome of 46 children with autoimmune hepatitis].
Cao LL; Zhang M; Zhu SS; Dong Y; Xu ZQ; Chen DW; Wang LM; Wang FC; Gan Y; Yan JG; Wang P; Li AQ
Zhonghua Er Ke Za Zhi; 2019 Jan; 57(1):40-45. PubMed ID: 30630230
[No Abstract] [Full Text] [Related]
3. Reversibility of cirrhosis in chronic hepatitis B.
Malekzadeh R; Mohamadnejad M; Rakhshani N; Nasseri-Moghaddam S; Merat S; Tavangar SM; Sohrabpour AA
Clin Gastroenterol Hepatol; 2004 Apr; 2(4):344-7. PubMed ID: 15067631
[TBL] [Abstract][Full Text] [Related]
4. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy.
Verma S; Gunuwan B; Mendler M; Govindrajan S; Redeker A
Am J Gastroenterol; 2004 Aug; 99(8):1510-6. PubMed ID: 15307869
[TBL] [Abstract][Full Text] [Related]
5. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy.
Cotler SJ; Jakate S; Jensen DM
J Clin Gastroenterol; 2001; 32(5):428-30. PubMed ID: 11319316
[TBL] [Abstract][Full Text] [Related]
6. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment.
Dufour JF; DeLellis R; Kaplan MM
Dig Dis Sci; 1998 Dec; 43(12):2573-6. PubMed ID: 9881484
[TBL] [Abstract][Full Text] [Related]
7. Hepatic stellate cell activation and hepatic fibrosis in children with type 1 autoimmune hepatitis: an immunohistochemical study of paired liver biopsies before treatment and after clinical remission.
Maia JM; Maranhão Hde S; Sena LV; Rocha LR; Medeiros IA; Ramos AM
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):264-9. PubMed ID: 20009940
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis.
Dhaliwal HK; Hoeroldt BS; Dube AK; McFarlane E; Underwood JC; Karajeh MA; Gleeson D
Am J Gastroenterol; 2015 Jul; 110(7):993-9. PubMed ID: 26010310
[TBL] [Abstract][Full Text] [Related]
9. [Histological regression of liver fibrosis with immunosuppressive therapy in autoimmune hepatitis].
Valera JM; Smok G; Márquez S; Poniachik J; Brahm J
Gastroenterol Hepatol; 2011 Jan; 34(1):10-5. PubMed ID: 21194803
[TBL] [Abstract][Full Text] [Related]
10. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis.
Mohamadnejad M; Malekzadeh R; Nasseri-Moghaddam S; Hagh-Azali S; Rakhshani N; Tavangar SM; Sedaghat M; Alimohamadi SM
Dig Dis Sci; 2005 Mar; 50(3):547-51. PubMed ID: 15810640
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
12. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R
J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis.
Ferreira AR; Roquete ML; Toppa NH; de Castro LP; Fagundes ED; Penna FJ
J Pediatr Gastroenterol Nutr; 2008 Jan; 46(1):65-70. PubMed ID: 18162836
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis.
Efe C; Cengiz M; Kahramanoğlu-Aksoy E; Yilmaz B; Özşeker B; Beyazt Y; Tanoğlu A; Purnak T; Kav T; Turhan T; Ozenirler S; Ozaslan E; Wahlin S
Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):649-54. PubMed ID: 25860719
[TBL] [Abstract][Full Text] [Related]
15. Reversibility of cirrhosis in autoimmune hepatitis.
Malekzadeh R; Mohamadnejad M; Nasseri-Moghaddam S; Rakhshani N; Tavangar SM; Sohrabpour AA; Tahaghoghi S
Am J Med; 2004 Jul; 117(2):125-9. PubMed ID: 15234650
[No Abstract] [Full Text] [Related]
16. Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis.
Puustinen L; Boyd S; Mustonen H; Arkkila P; Arola J; Färkkilä M
Scand J Gastroenterol; 2017 Mar; 52(3):321-327. PubMed ID: 27846740
[TBL] [Abstract][Full Text] [Related]
17. The natural history of autoimmune hepatitis presenting with jaundice.
Panayi V; Froud OJ; Vine L; Laurent P; Woolson KL; Hunter JG; Madden RG; Miller C; Palmer J; Harris N; Mathew J; Stableforth B; Murray IA; Dalton HR
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):640-5. PubMed ID: 24694760
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune hepatitis in African Americans: presenting features and response to therapy.
Lim KN; Casanova RL; Boyer TD; Bruno CJ
Am J Gastroenterol; 2001 Dec; 96(12):3390-4. PubMed ID: 11774954
[TBL] [Abstract][Full Text] [Related]
19. Serum hyaluronic acid and laminin as biomarkers in liver fibrosis.
Parsian H; Rahimipour A; Nouri M; Somi MH; Qujeq D; Fard MK; Agcheli K
J Gastrointestin Liver Dis; 2010 Jun; 19(2):169-74. PubMed ID: 20593050
[TBL] [Abstract][Full Text] [Related]
20. Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.
Czaja AJ
Aliment Pharmacol Ther; 2014 Feb; 39(4):385-406. PubMed ID: 24387318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
